# Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia

> **NCT03796390** · PHASE1 · UNKNOWN · sponsor: **Hebei Senlang Biotechnology Inc., Ltd.** · enrollment: 15 (estimated)

## Conditions studied

- Acute Myelocytic Leukemia

## Interventions

- **BIOLOGICAL:** CD123 CAR-T cells

## Key facts

- **NCT ID:** NCT03796390
- **Lead sponsor:** Hebei Senlang Biotechnology Inc., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-26
- **Primary completion:** 2020-11-06
- **Final completion:** 2021-06-06
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2019-01-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03796390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03796390, "Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03796390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*